【摘要】 目的 探究信迪利单抗联合奥沙利铂、替吉奥对胃癌的治疗价值。方法 将100例胃癌患者，按治疗方法分为两组，对照组采用奥沙利铂、替吉奥方案治疗，观察组在对照组基础上联合信迪利单抗治疗，比较两组临床疗效、肿瘤标记物、血清炎性因子及不良反应。结果 观察组客观缓解率、疾病控制率高于对照组，治疗2个周期后，观察组CEA、CA125、TNF-α、IL-6水平低于对照组，CD4~+、CD4~+/CD8~+高于对照组，差异有统计学意义(P<0.05);两组CD8~+比较，差异无统计学意义(P>0.05);两组不良反应比较，差异无统计学意义(P>0.05)。结论 信迪利单抗联合奥沙利铂、替吉奥治疗胃癌效果确切，可降低肿瘤标记物及血清炎性因子水平，改善患者免疫功能，且安全性可控。更多还原

【Abstract】 Objective To explore the treatment of gastric cancer with sindilizumab combined with oxaliplatin and Teggi.Methods 100 cases of stomach cancer were divided into 2 groups according to treatment methods.The control group was treated with oxaliplatin and Tegor, and the observation group was treated with sintilizumab on the basis of the control group.The clinical efficacy, tumor markers, serum inflammatory factors and adverse reactions were compared between the 2 groups.Results The objective remission rate and disease control rate in the observation group were higher than those in the control group.After 2 cycles of treatment, CEA,CA125,TNF-α and IL-6 in the observation group were lower than those in the control group, and CD4~+and CD4~+/CD8~+were higher than those in the control group, the differences were statistically significant(P<0.05).There was no significant difference in CD8~+between the 2 groups(P>0.05).There was no significant difference in adverse reactions between the 2 groups(P>0.05).Conclusion Sindilizumab combined with oxaliplatin and Ticeo regimen have definite effects in the treatment of gastric cancer, which can reduce the levels of tumor markers and serum inflammatory factors, improve immune function, and have controllable safety.更多还原